<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640081</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000589635</org_study_id>
    <secondary_id>MRC-CTU-COIN-B/CR11</secondary_id>
    <secondary_id>EUDRACT:2006-003049-17</secondary_id>
    <secondary_id>ISRCTN38375681</secondary_id>
    <secondary_id>EU-20828</secondary_id>
    <secondary_id>MERCK-MRC-CTU-COIN-B/CR11</secondary_id>
    <nct_id>NCT00640081</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Two-arm Phase II Randomised Trial of Intermittent Chemotherapy Plus Continuous Cetuximab and of Intermittent Chemotherapy Plus Intermittent Cetuximab in First Line Treatment of Patients With K-ras-normal (Wild-type) Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cheryl Pugh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Research Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,&#xD;
      such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor&#xD;
      cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing&#xD;
      substances to them. It is not yet known whether giving combination chemotherapy together with&#xD;
      intermittent cetuximab is more effective than combination chemotherapy given together with&#xD;
      continuous cetuximab in treating colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving combination chemotherapy together&#xD;
      with intermittent cetuximab to see how well it works compared to combination chemotherapy&#xD;
      given together with continuous cetuximab as first-line therapy in treating patients with&#xD;
      advanced or metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the activity, in terms of failure-free survival, of patients with&#xD;
           K-ras-normal (wild type) advanced and/or metastatic colorectal cancer treated with&#xD;
           intermittent combination chemotherapy comprising oxaliplatin, leucovorin calcium, and&#xD;
           fluorouracil (OxMdG) or oxaliplatin and capecitabine (XELOX) and intermittent vs&#xD;
           continuous cetuximab as first-line therapy.&#xD;
&#xD;
        -  To compare the safety and feasibility of these regimens in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the safety of cetuximab reintroduction, in terms of frequency of grade 3-4&#xD;
           allergic reactions in these patients.&#xD;
&#xD;
        -  To compare improvement in disease control (i.e., complete response plus partial response&#xD;
           plus stable disease) at 24 weeks in patients treated with these regimens.&#xD;
&#xD;
        -  To compare overall and progression-free survival of patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  To compare response rates at 12, 24, and 36 weeks in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  To compare toxicity of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomised to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (intermittent chemotherapy and intermittent cetuximab): Patients receive 1 of the&#xD;
           following combination chemotherapy and cetuximab regimens:&#xD;
&#xD;
             -  OxMdG: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over&#xD;
                2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2.&#xD;
                Patients also receive cetuximab IV over 1-2 hours on days 1 and 8. Treatment&#xD;
                repeats every 14 days for up to 6 courses (12 weeks) in the absence of disease&#xD;
                progression or unacceptable toxicity.&#xD;
&#xD;
             -  XELOX (for patients with line-related problems): Patients receive oxaliplatin IV&#xD;
                over 2 hours on day 1 and oral capecitabine twice daily on days 1-15 (28 doses).&#xD;
                Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment&#xD;
                repeats every 21 days for up to 4 courses (12 weeks) in the absence of disease&#xD;
                progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of 12 weeks of study therapy, patients with disease progression are removed&#xD;
      from study. Patients with stable or responding disease stop treatment with OxMdG or XELOX and&#xD;
      cetuximab and undergo clinical evaluation at least every 6 weeks until disease progression or&#xD;
      clinical deterioration. Upon evidence of disease progression or clinical deterioration,&#xD;
      patients restart treatment with OxMdG or XELOX and cetuximab as before and continue to&#xD;
      alternate 12 weeks of treatment with treatment breaks in the absence of disease progression&#xD;
      or unacceptable toxicity. Patients with disease progression during study therapy stop&#xD;
      treatment and proceed to second-line therapy or best supportive care.&#xD;
&#xD;
        -  Arm II (intermittent chemotherapy and continuous cetuximab): Patients receive OxMdG or&#xD;
           XELOX and cetuximab for 12 weeks as in arm I. Patients with disease progression after 12&#xD;
           weeks of study therapy are removed from study. Patients with stable or responding&#xD;
           disease* after 12 weeks of study therapy stop treatment with OxMdG or XELOX and continue&#xD;
           treatment with cetuximab weekly as monotherapy in the absence of disease progression or&#xD;
           unacceptable toxicity. Patients undergo clinical evaluation as in arm I. Upon&#xD;
           progression, patients restart treatment with OxMdG or XELOX and continue cetuximab, as&#xD;
           before, alternating 12 weeks of combined OxMdG or XELOX and cetuximab therapy with&#xD;
           cetuximab monotherapy. Patients with disease progression during study therapy stop&#xD;
           treatment and proceed to second-line therapy as in arm I.&#xD;
&#xD;
      Previously collected tumor tissue samples are obtained at baseline and analyzed by IHC for&#xD;
      EGFR status of tumor.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 12 weeks.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival at 10 months</measure>
    <time_frame>10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of cetuximab reintroduction, in terms of risk of grade 3-4 allergic reactions</measure>
    <time_frame>12, 24 and 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving disease control (complete response plus partial response plus stable disease) at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 12, 24 and 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 12, 24 and 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>at 12, 24 and 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of each treatment regimen by NCI CTCAE v3.0</measure>
    <time_frame>at 12, 24 and 36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermittent chemotherapy plus intermittent cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period off all therapy, with reintroduction of the same chemotherapy and cetuximab regimen for a further 12 weeks after initial progression off treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent chemotherapy plus continuous cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period of withdrawal of the chemotherapy, but continued weekly cetuximab monotherapy (maintenance cetuximab), with reintroduction of the same chemotherapy regimen to the cetuximab for a further 12 weeks after initial progression off chemotherapy treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of colorectal adenocarcinoma, defined by 1 of the following:&#xD;
&#xD;
               -  Prior or current histologically confirmed primary adenocarcinoma of colon or&#xD;
                  rectum with clinical or radiological evidence of advanced and/or metastatic&#xD;
                  disease&#xD;
&#xD;
               -  Histologically and cytologically confirmed metastatic adenocarcinoma with&#xD;
                  clinical and/or radiological evidence of colorectal primary tumor&#xD;
&#xD;
          -  Unidimensionally measurable disease by RECIST criteria&#xD;
&#xD;
          -  Inoperable metastatic or locoregional disease&#xD;
&#xD;
               -  Potentially resectable liver metastases allowed provided the following criteria&#xD;
                  are met:&#xD;
&#xD;
                    -  Fewer than 4 unilobar liver metastases, each &lt; 4 cm in size and without&#xD;
                       major vascular involvement&#xD;
&#xD;
                    -  No combination chemotherapy allowed prior to the planned resection of&#xD;
                       operable liver metastases&#xD;
&#xD;
          -  No confirmed K-ras mutation of tumor after screening&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Must be considered fit to undergo combination chemotherapy&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 50mL/min OR glomerular filtration rate ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No severe uncontrolled concurrent medical illness (including poorly controlled angina&#xD;
             or myocardial infarction within the past 12 weeks) likely to interfere with protocol&#xD;
             treatments&#xD;
&#xD;
          -  No psychiatric or neurological condition that would preclude study compliance with&#xD;
             oral medication or giving informed consent&#xD;
&#xD;
          -  No partial or complete bowel obstruction&#xD;
&#xD;
          -  No preexisting neuropathy &gt; grade 1&#xD;
&#xD;
          -  No prior or current malignant disease which, in the judgement of the treating&#xD;
             investigator, is likely to interfere with COIN-B treatment or assessment of response&#xD;
&#xD;
          -  No patients with known hypersensitivity reactions to any of the components of the&#xD;
             study treatments&#xD;
&#xD;
          -  No proven dihydropyrimidine dehydrogenase deficiency (DPD) or personal or family&#xD;
             history of DPD&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior systemic palliative chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  More than 1 month since prior adjuvant chemotherapy comprising fluorouracil (with or&#xD;
             without leucovorin calcium), capecitabine, or irinotecan hydrochloride&#xD;
&#xD;
          -  More than 1 month since prior chemoradiotherapy comprising fluorouracil (with or&#xD;
             without leucovorin calcium) or capecitabine for rectal cancer&#xD;
&#xD;
          -  No ongoing requirement for contraindicated concurrent medication&#xD;
&#xD;
          -  No concurrent enrollment in any type of study other than observational studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harpreet S. Wasan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bank of Cyprus Oncology Centre</name>
      <address>
        <city>Nicosia</city>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <state>England</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Oncology Centre at Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <state>England</state>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essex County Hospital</name>
      <address>
        <city>Colchester</city>
        <state>England</state>
        <zip>C03 3NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorset County Hospital</name>
      <address>
        <city>Dorchester</city>
        <state>England</state>
        <zip>DT1 2JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterborough Hospitals Trust</name>
      <address>
        <city>Peterborough</city>
        <state>England</state>
        <zip>PE3 6DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Staffordshire</name>
      <address>
        <city>Stoke-On-Trent</city>
        <state>England</state>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <state>Wales</state>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hereford County Hospital</name>
      <address>
        <city>Hereford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas' hospitals</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorset Cancer Centre, Poole Hospital</name>
      <address>
        <city>Poole</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southport and Ormskirk</name>
      <address>
        <city>Southport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Helens and Whiston hospitals</name>
      <address>
        <city>St Helens</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warrington and Halton Hospitals</name>
      <address>
        <city>Warrington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cyprus</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ctu.mrc.ac.uk/our_research/research_areas/cancer/studies/coin_b/</url>
    <description>Trial Summary on Sponsor's Website with trial citations</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical Research Council</investigator_affiliation>
    <investigator_full_name>Cheryl Pugh</investigator_full_name>
    <investigator_title>Clinical Project manager for COINB for Sponsor</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication</ipd_description>
    <ipd_url>http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70106-8/abstract</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70106-8/abstract</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

